{"id":1199,"date":"2009-01-01T12:01:00","date_gmt":"2009-01-01T11:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2009\/rosuvastatin-neues-wundermittel-auch-fuer-gesunde-mit-normalem-cholesterin-die-jupiter-studie"},"modified":"2022-03-17T14:11:32","modified_gmt":"2022-03-17T13:11:32","slug":"rosuvastatin-neues-wundermittel-auch-fuer-gesunde-mit-normalem-cholesterin-die-jupiter-studie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2009\/rosuvastatin-neues-wundermittel-auch-fuer-gesunde-mit-normalem-cholesterin-die-jupiter-studie","title":{"rendered":"Rosuvastatin: neues Wundermittel auch f\u00fcr Gesunde mit normalem Cholesterin? Die JUPITER-Studie"},"content":{"rendered":"<p>Rosuvastatin, ein typisches \u201eMe-too-P\u00e4parat\u201d zur Cholesterinsenkung, ist in \u00d6sterreich &#8211; im Gegensatz zu Deutschland &#8211; zugelassen und wird kr\u00e4ftig beworben (Crestor\u00ae, AstraZeneca). Die j\u00fcngst im N. Engl. J. Med. publizierte JUPITER-Studie kommt dem Hersteller und Sponsor nun sehr gelegen (1). Scheinbar eindrucksvoll konnte an einer Studienpopulation von 17 802 Probanden mit normalen Cholesterinwerten (Ausgangs-LDL-Cholesterin < [&hellip;]\n<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Rosuvastatin, ein typisches \u201eMe-too-P\u00e4parat\u201d zur Cholesterinsenkung, ist in \u00d6sterreich &#8211; im Gegensatz zu Deutschland &#8211; zugelassen und wird kr\u00e4ftig beworben (Crestor\u00ae, AstraZeneca). Die j\u00fcngst im N. Engl. J. Med. publizierte JUPITER-Studie kommt dem Hersteller und Sponsor nun sehr gelegen (1). Scheinbar eindrucksvoll konnte an einer Studienpopulation von 17 802 Probanden mit normalen Cholesterinwerten (Ausgangs-LDL-Cholesterin < [&hellip;]\n<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[495,60,2495,451,2494,449,71,68,455,453,2997,498,456,65,1043,56,443],"class_list":["post-1199","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-angina-pectoris","tag-apoplektischer-insult","tag-c-reaktives-protein","tag-cholesterinsynthese-hemmer","tag-crp","tag-cse-hemmer","tag-herzinfarkt","tag-hirninfarkt","tag-hmg-coa-reduktase-hemmer","tag-hypercholesterinaemie","tag-jupiter-studie","tag-koronare-herzkrankheit","tag-lipidsenker","tag-myokardinfarkt","tag-rosuvastatin","tag-schlaganfall","tag-statine"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1199"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1199\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}